Azalea is delivering therapies with unparalleled accuracy – first to the right cells, then to the precise genetic locus – creating life-changing treatments inside the body
Redefining precision genomic medicines, in vivo
The Science
Azalea Therapeutics is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo.
Azalea is pioneering a new way to turn a person’s own T cells into a powerful cancer therapy — directly inside the body. Instead of removing cells and manipulating them in a lab, we use precision genome editing tools to engineer T cells where they already live. At the center of our approach are Enveloped Delivery Vehicles, or EDVs. As highly selective couriers, EDVs are designed to specifically locate T cells within the patient and deliver our genome engineering cargo. Once inside the cell, the anti-cancer agent is inserted into a precise site in the genome, ensuring safe and potent modifications to fortify the T cells against cancers.
Why this matters:
- We aim to make cell therapy faster and more accessible by avoiding complex manufacturing outside the body.
- Our platform is designed for precision, so the right cells are safely programmed to effectively fight cancer.
- This technology has the potential to treat a wide range of cancers with a streamlined, scalable process.
Our goal is simple: develop next-generation delivery technologies to bring genetic engineering and cell therapies to more patients.
Our Team
Leadership
Co-founder, President and Chief Executive Officer
Chief Business Officer
Scientific co-founder
Scientific co-founder
Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences, UC Berkeley
Co-founder, Associate Professor of Medicine, UCSF
Co-founder, Professor of Bioengineering, Stanford University
Board of Directors
Partner, Third Rock Ventures
Venture Partner, Third Rock Ventures
Managing Director, RA Capital Management
Professor of Bioengineering, Stanford University
Associate Professor of Medicine, UCSF
Co-founder, President and Chief Executive Officer
Board Observers
Nobel Laureate in Chemistry and Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences, UC Berkeley
Investor, Yosemite
Investment Director, RA Capital Management
Investors
News
Filter
Publications
Filter
Careers
At Azalea Therapeutics, we’re a group of scientists and entrepreneurs passionate about developing next-generation genomic medicines for patients. We are always looking for scientifically curious, highly driven, and genuinely collaborative individuals who share the same passions to join our diverse team.
